Myomo (MYO) Net Cash Flow Growth (3y) (2019 - 2025)
Myomo (MYO) Net Cash Flow Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.69 Bn | 175.40 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.07 Bn | 98.85 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 67.93 Bn | 66.47 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.11 Bn | 44.44 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.60 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.99 Bn | 26.42 Bn | - | - |
| 9 | Koninklijke Philips | 24.05 Bn | 20.92 Bn | 2.07 Bn | -48.90% |
| 10 | Myomo | 43.85 Mn | 24.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 15.55% |
| Jun 30, 2025 | -27.69% |
| Mar 31, 2025 | -21.48% |
| Dec 31, 2024 | 82.87% |
| Sep 30, 2024 | 44.01% |
| Jun 30, 2024 | 28.37% |
| Mar 31, 2024 | -31.58% |
| Dec 31, 2023 | 62.15% |
| Sep 30, 2023 | -28.85% |
| Jun 30, 2023 | -2.98% |
| Mar 31, 2023 | -24.98% |
| Dec 31, 2022 | -158.38% |
| Sep 30, 2022 | -6.21% |
| Jun 30, 2022 | -1.74% |
| Mar 31, 2022 | -43.50% |
| Dec 31, 2021 | 46.42% |
| Sep 30, 2021 | 23.78% |
| Jun 30, 2021 | -14.30% |
| Mar 31, 2021 | 64.29% |
| Dec 31, 2020 | -28.89% |